Literature DB >> 15195100

PML regulates p53 stability by sequestering Mdm2 to the nucleolus.

Rosa Bernardi1, Pier Paolo Scaglioni, Stephan Bergmann, Henning F Horn, Karen H Vousden, Pier Paolo Pandolfi.   

Abstract

The promyelocytic leukaemia (PML) tumour-suppressor protein potentiates p53 function by regulating post-translational modifications, such as CBP-dependent acetylation and Chk2-dependent phosphorylation, in the PML-Nuclear Body (NB). PML was recently shown to interact with the p53 ubiquitin-ligase Mdm2 (refs 4-6); however, the mechanism by which PML regulates Mdm2 remains unclear. Here, we show that PML enhances p53 stability by sequestering Mdm2 to the nucleolus. We found that after DNA damage, PML and Mdm2 accumulate in the nucleolus in an Arf-independent manner. In addition, we found that the nucleolar localization of PML is dependent on ATR activation and phosphorylation of PML by ATR. Notably, in Pml(-/-) cells, sequestration of Mdm2 to the nucleolus was impaired, as well as p53 stabilization and the induction of apoptosis. Furthermore, we demonstrate that PML physically associates with the nucleolar protein L11, and that L11 knockdown impairs the ability of PML to localize to nucleoli after DNA damage. These findings demonstrate an unexpected role of PML in the nucleolar network for tumour suppression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195100     DOI: 10.1038/ncb1147

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  133 in total

1.  Resistance to rabies virus infection conferred by the PMLIV isoform.

Authors:  Danielle Blondel; Sabrina Kheddache; Xavier Lahaye; Laurent Dianoux; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 2.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

3.  Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.

Authors:  Yunyun Geng; Shamci Monajembashi; Anwen Shao; Di Cui; Weiyong He; Zhongzhou Chen; Peter Hemmerich; Jun Tang
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

4.  Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.

Authors:  Daniel Bailey; Peter O'Hare
Journal:  Biochem J       Date:  2005-12-01       Impact factor: 3.857

5.  PML regulates PER2 nuclear localization and circadian function.

Authors:  Takao Miki; Zhixiang Xu; Misty Chen-Goodspeed; Mingguang Liu; Anita Van Oort-Jansen; Michael A Rea; Zhaoyang Zhao; Cheng Chi Lee; Kun-Sang Chang
Journal:  EMBO J       Date:  2012-01-24       Impact factor: 11.598

6.  Insights into nuclear organization in plants as revealed by the dynamic distribution of Arabidopsis SR splicing factors.

Authors:  Vinciane Tillemans; Isabelle Leponce; Glwadys Rausin; Laurence Dispa; Patrick Motte
Journal:  Plant Cell       Date:  2006-11-17       Impact factor: 11.277

7.  Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition.

Authors:  Yaron Shav-Tal; Janna Blechman; Xavier Darzacq; Cristina Montagna; Billy T Dye; James G Patton; Robert H Singer; Dov Zipori
Journal:  Mol Biol Cell       Date:  2005-03-09       Impact factor: 4.138

8.  p63 deficiency activates a program of cellular senescence and leads to accelerated aging.

Authors:  William M Keyes; Ying Wu; Hannes Vogel; Xuecui Guo; Scott W Lowe; Alea A Mills
Journal:  Genes Dev       Date:  2005-08-17       Impact factor: 11.361

9.  Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage.

Authors:  Adam S Mastrocola; Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2009-12-08

Review 10.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.